

Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa

Author(s): [Alexandre R. de Mello Schier](#), [Natalia P. de Oliveira Ribeiro](#), [Danielle S. Coutinho](#), [Sergio Machado](#), [Oscar Arias-Carrion](#), [Jose A. Crippa](#), [Antonio W. Zuardi](#), [Antonio E. Nardi](#), [Adriana C. Silva](#).

Journal Name: CNS & Neurological Disorders - Drug Targets

Volume 13 , Issue 6 , 2014

Abstract:

Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.